Abstract
We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.
| Original language | English |
|---|---|
| Pages (from-to) | 1217-1224 |
| Number of pages | 8 |
| Journal | Human Vaccines and Immunotherapeutics |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 3 2016 |
Fingerprint
Keywords
- case control studies
- hospital
- Influenza
- Influenza vaccine
- multicentre studies
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology
Cite this
Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14 : Results from the InNHOVE network. / Rondy, M.; Castilla, J.; Launay, O.; Costanzo, S.; Ezpeleta, C.; Galtier, F.; de Gaetano Donati, K.; Ezpeleta, Carmen; Moren, A.; Beristain, Xabier; Chamorro, Judith; Gabari, Mercedes; Artajo, Pilar; Lameiro, Francisco; Barrado, Laura; Ortega, Maite; Torres, Montse; García Irure, José Javier; Irisarri, Fátima; García Cenoz, Manuel; Guevara, Marcela; Casado, Itziar; Díaz, Jorge; Martínez-Baz, Iván; Castilla, Jesús; Lenzi, Nezha; Lesieur, Zineb; Bonmarin, Isabelle; Merle, Corinne; Foulongne, Vincent; Letois, Flavie; Driss, Valérie; Géraud, Philippe; Bourdin, Arnaud; Landreau, Liliane; Konaté, Amadou; Corne, Philippe; Sebbane, Mustapha; Klouche, Kada; Léglise, Marie Suzanne; Loulergue, Pierre; Kanaan, Reem; Dumas, Florence; Krivine, Anne; Moncilovic, Sonia; Ali, Nadine; Duval, Xavier; Costa, Yolande; Aït Naman, Rachid; Yazdapanah, Yazdan; Caseris, Marion; Dournon, Nathalie; Papo, Thomas; Dossier, Antoine; Bécheur, Hakim; Pelletier, Anne Laure; Mal, Hervé; Marceau, Armelle; Aubier, Michel; Bories, Raphaêl; Casalino, Enrique; Choquet, Christophe; Houhou, Nadhira; Vanhems, Philippe; Régis, Corinne; Jouneau, Stéphane; Lainé, Fabrice; Tattevin, Pierre; Beuzit, Luc; Thébault, Elise; Fey, Sophie; Lagathu et Sophie Cha, Gisele; Postil, Déborah; Alcoléa, Sébastien; Rogez, Sylvie; Valette, Martine; Lina, Bruno; de Gaetano Donati, Katleen; Cauda, Roberto; Taccari, Francesco; Santangelo, Rosaria; Perlasca, Francesco; Fichera, Giovanni; Dara, Marianna; Costanzo, Simona; Iacoviello, Licia; Olivieri, Marco.
In: Human Vaccines and Immunotherapeutics, Vol. 12, No. 5, 03.05.2016, p. 1217-1224.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14
T2 - Results from the InNHOVE network
AU - Rondy, M.
AU - Castilla, J.
AU - Launay, O.
AU - Costanzo, S.
AU - Ezpeleta, C.
AU - Galtier, F.
AU - de Gaetano Donati, K.
AU - Ezpeleta, Carmen
AU - Moren, A.
AU - Beristain, Xabier
AU - Chamorro, Judith
AU - Gabari, Mercedes
AU - Artajo, Pilar
AU - Lameiro, Francisco
AU - Barrado, Laura
AU - Ortega, Maite
AU - Torres, Montse
AU - García Irure, José Javier
AU - Irisarri, Fátima
AU - García Cenoz, Manuel
AU - Guevara, Marcela
AU - Casado, Itziar
AU - Díaz, Jorge
AU - Martínez-Baz, Iván
AU - Castilla, Jesús
AU - Lenzi, Nezha
AU - Lesieur, Zineb
AU - Bonmarin, Isabelle
AU - Merle, Corinne
AU - Foulongne, Vincent
AU - Letois, Flavie
AU - Driss, Valérie
AU - Géraud, Philippe
AU - Bourdin, Arnaud
AU - Landreau, Liliane
AU - Konaté, Amadou
AU - Corne, Philippe
AU - Sebbane, Mustapha
AU - Klouche, Kada
AU - Léglise, Marie Suzanne
AU - Loulergue, Pierre
AU - Kanaan, Reem
AU - Dumas, Florence
AU - Krivine, Anne
AU - Moncilovic, Sonia
AU - Ali, Nadine
AU - Duval, Xavier
AU - Costa, Yolande
AU - Aït Naman, Rachid
AU - Yazdapanah, Yazdan
AU - Caseris, Marion
AU - Dournon, Nathalie
AU - Papo, Thomas
AU - Dossier, Antoine
AU - Bécheur, Hakim
AU - Pelletier, Anne Laure
AU - Mal, Hervé
AU - Marceau, Armelle
AU - Aubier, Michel
AU - Bories, Raphaêl
AU - Casalino, Enrique
AU - Choquet, Christophe
AU - Houhou, Nadhira
AU - Vanhems, Philippe
AU - Régis, Corinne
AU - Jouneau, Stéphane
AU - Lainé, Fabrice
AU - Tattevin, Pierre
AU - Beuzit, Luc
AU - Thébault, Elise
AU - Fey, Sophie
AU - Lagathu et Sophie Cha, Gisele
AU - Postil, Déborah
AU - Alcoléa, Sébastien
AU - Rogez, Sylvie
AU - Valette, Martine
AU - Lina, Bruno
AU - de Gaetano Donati, Katleen
AU - Cauda, Roberto
AU - Taccari, Francesco
AU - Santangelo, Rosaria
AU - Perlasca, Francesco
AU - Fichera, Giovanni
AU - Dara, Marianna
AU - Costanzo, Simona
AU - Iacoviello, Licia
AU - Olivieri, Marco
PY - 2016/5/3
Y1 - 2016/5/3
N2 - We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.
AB - We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.
KW - case control studies
KW - hospital
KW - Influenza
KW - Influenza vaccine
KW - multicentre studies
UR - http://www.scopus.com/inward/record.url?scp=84976415449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976415449&partnerID=8YFLogxK
U2 - 10.1080/21645515.2015.1126013
DO - 10.1080/21645515.2015.1126013
M3 - Article
VL - 12
SP - 1217
EP - 1224
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
SN - 2164-5515
IS - 5
ER -